ACORN CAPITAL ADVISORS, LLC
NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$364.0M2026 Q3
Positions22
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.88.0%
What Changed This Quarter?
Top Holdings
CGON
CG Oncology
22.0%
URGN
UroGen Pharma
18.4%
PBYI
Puma Biotechnology
11.3%
CADL
Candel Therapeutics
10.0%
TRVI
Trevi Therapeutics
8.4%
HELP
Helus Pharma
5.2%
JBIO
Jade Biosciences
3.8%
BCAX
Bicara Therapeutics
3.4%
New / Increased
2 new · 6 increased
ANTXNEW
AN2 Therapeutics
1.9%
ANNXNEW
Annexon
1.3%
ENGN
Eugene Therapeutics
2.1%
+199.8%
LONA
Leonabio
1.1%
+80.4%
Yarrow Biosci…
Yarrow Biosciences
0.2%
+2146.0%
AURA
Aura Biosciences
1.8%
+10.4%
BCAX
Bicara Therapeutics
3.4%
+3.9%
Reduced / Exited
3 reduced · 0 sold out
URGN
Urogen Pharma
18.4%
-1.5%
WHWK
Whitehawk Therapeutics
1.0%
-18.2%
KPTI
Karyopharm Therapeutics
0.4%
-19.5%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.